OptimizeRx (OPRX)
(Real Time Quote from BATS)
$6.57 USD
-0.06 (-0.91%)
Updated Oct 14, 2024 02:38 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Cash flow Statements
Fiscal Year End for OptimizeRx Corp falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -17.57 | -11.44 | 0.38 | -2.21 | -3.14 |
Depreciation/Amortization & Depletion | 2.61 | 2.02 | 1.97 | 1.97 | 1.18 |
Net Change from Assets/Liabilities | -7.85 | 3.96 | -7.31 | -9.69 | -1.88 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 15.57 | 16.11 | 5.69 | 3.62 | 2.18 |
Net Cash From Operating Activities | -7.24 | 10.65 | 0.73 | -6.31 | -1.66 |
Property & Equipment | -0.86 | -0.24 | -0.46 | -0.11 | -0.09 |
Acquisition/ Disposition of Subsidiaries | -80.41 | -2.00 | -0.02 | 0.00 | -8.99 |
Investments | 55.93 | -55.93 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | -0.01 | -1.50 |
Net Cash from Investing Activities | -25.34 | -58.18 | -0.49 | -0.12 | -10.58 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | -7.80 | -18.95 | 75.54 | 2.49 | 22.18 |
Issuance (Repayment) of Debt | 36.02 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | -1.61 | -4.39 | 0.00 |
Net Cash from Financing Activities | 28.22 | -18.95 | 73.92 | -1.90 | 22.18 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -4.36 | -66.47 | 74.16 | -8.34 | 9.94 |
Cash at Beginning of Period | 18.21 | 84.68 | 10.52 | 18.85 | 8.91 |
Cash at End of Period | 13.85 | 18.21 | 84.68 | 10.52 | 18.85 |
Diluted Net EPS | -1.03 | -0.64 | 0.02 | -0.15 | -0.23 |
Fiscal Year End for OptimizeRx Corp falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -10.91 | -6.90 | -17.57 | -13.42 |
Depreciation/Amortization & Depletion | NA | 2.51 | 1.25 | 2.61 | 1.40 |
Net Change from Assets/Liabilities | NA | 5.25 | 4.61 | -7.85 | -0.52 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 6.06 | 3.16 | 15.57 | 11.57 |
Net Cash From Operating Activities | NA | 2.90 | 2.12 | -7.24 | -0.98 |
Property & Equipment | NA | -0.24 | -0.15 | -0.86 | -1.64 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | -80.41 | 0.00 |
Investments | NA | 0.00 | 0.00 | 55.93 | 2.31 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | -0.24 | -0.15 | -25.34 | 0.66 |
Uses of Funds
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 0.00 | 0.00 | -7.80 | -7.38 |
Issuance (Repayment) of Debt | NA | -1.00 | -0.50 | 36.02 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | -0.56 | -0.14 | 0.00 | -0.59 |
Net Cash from Financing Activities | NA | -1.56 | -0.64 | 28.22 | -7.97 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | 1.11 | 1.33 | -4.36 | -8.29 |
Cash at Beginning of Period | NA | 13.85 | 13.85 | 18.21 | 18.21 |
Cash at End of Period | NA | 14.96 | 15.18 | 13.85 | 9.92 |
Diluted Net EPS | NA | -0.22 | -0.38 | -0.25 | -0.17 |